It is interesting to note that along with an increase in CD16+ NK cell counts in patients with treatment-resistant pains, the CD16+ monocyte counts decreased significantly, and a similar trend was observed in patients with treatment-related amenorrhea (F = 5.577, p = 0.065). This evidence concerns the gene FCGR3A and amenorrhea.